ScripBiohaven’s stock price closed down 15.2% at $19.84 on 25 April on the news that the company withdrew its application for European Medicines Agency approval of troriluzole in the treatment of spinocere
ScripSpecial purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative
ScripWith investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue
ScripTwelve biopharmaceutical companies announced venture capital financings totaling $672m between 7 and 11 February, which was another relatively quiet week for public company offerings. With biotechnolo